8-K: LifeMD Reports Strong Q4 2024 Results with 43% Revenue Increase and Introduces Optimistic 2025 Guidance

LifeMD announces a 43% year-over-year increase in consolidated revenues to $64.3 million for Q4 2024, alongside positive full-year cash flow and promising 2025 financial guidance.

Summary

• LifeMD, Inc. reported its financial results for the three months and year ended December 31, 2024.
• The company's consolidated revenues for Q4 2024 increased by 43% year-over-year to $64.3 million, with telehealth revenue up by 60%.
• Adjusted EBITDA for Q4 2024 increased by 78% to $9.0 million, and telehealth adjusted EBITDA increased by 396% to $5.9 million.
• Full-year cash flow from operations increased by 99% to $17.5 million, resulting in positive full-year net cash flow.
• LifeMD exited 2024 with over $35 million in cash.
• The company introduced 2025 guidance, projecting consolidated revenue between $265 million and $275 million and consolidated adjusted EBITDA between $30 million and $32 million.

Sentiment

Score: 9

Explanation: The document presents a highly positive outlook with strong financial results, significant growth in key areas, and optimistic future guidance. The management's commentary further reinforces the positive sentiment.

Positives

• LifeMD achieved record quarterly revenue and adjusted EBITDA.
• The company experienced accelerated growth across its core telehealth brands.
• The weight management program showed significant growth.
• The WorkSimpli business returned to growth, with adjusted EBITDA exceeding $1 million per month during the quarter.
• LifeMD's Medicare launch is slated for April 1 and could be a significant growth driver for the weight management program.
• The company has begun laying the groundwork for the launch of its virtual-first behavioral health offering followed by a women's health specialty offering later this year.
• Telehealth active subscribers increased 27% to approximately 275,000 at quarter-end.
• WorkSimpli active subscribers increased 3% to approximately 164,000 at quarter-end and increased sequentially by approximately 3,000 subscribers.

Negatives

• Gross margin decreased from 88% to 85% due to one-time start-up costs with a new pharmacy and revenue mix changes, although it is expected to return to a range of 88% to 90% in 2025.
• GAAP net loss was $0.9 million or $0.02 per share for Q4 2024.

Risks

• GLP-1 market dynamics continue to change with semaglutide coming off shortage, which could impact the weight management program.
• The company's future performance is subject to risks and uncertainties, including those identified in its filings with the Securities and Exchange Commission.

Future Outlook

LifeMD anticipates consolidated revenue of $265 million to $275 million and consolidated adjusted EBITDA of $30 million to $32 million for the full year 2025.

Management Comments

• Justin Schreiber, Chairman and CEO of LifeMD, highlighted the growth of the weight management program and the upcoming Medicare launch as significant growth drivers.
• Marc Benathen, Chief Financial Officer of LifeMD, reported that the WorkSimpli business returned to growth and that the company is well-positioned for another year of record growth and profitability.

Industry Context

LifeMD's focus on virtual primary care and telehealth aligns with the growing trend of digital health solutions. The company's expansion into weight management, hormone therapy, behavioral health, and women's health positions it to capture a larger share of the healthcare market. The integration with LillyDirect to provide affordable access to Zepbound demonstrates a proactive approach to addressing market dynamics and patient needs.

Comparison to Industry Standards

• Teladoc Health, a major player in the telehealth industry, reported revenue growth of 8% year-over-year in its most recent quarter, while LifeMD's telehealth revenue grew by 60%.
• Amwell, another telehealth company, has been focusing on expanding its virtual care platform and partnerships, similar to LifeMD's strategy of launching new specialty offerings and integrating with pharmacy benefits infrastructure.
• Companies like Hims & Hers Health are also focusing on specific areas like men's and women's health, which aligns with LifeMD's expansion into these areas.

Legal Proceedings

• The company included litigation costs related to a class action complaint alleging, inter alia, unauthorized disclosure of certain information of class members to third parties (the Marden v. LifeMD, Inc. case).

Stakeholder Impact

• Shareholders can expect continued growth and profitability based on the company's financial results and guidance.
• Employees may benefit from the company's expansion and new initiatives.
• Customers will have access to a wider range of virtual care services.
• Suppliers and creditors can expect continued business and timely payments.

Next Steps

• LifeMD will host a conference call to discuss the company's financial results and outlook.
• The company plans to launch its Medicare program on April 1.
• LifeMD intends to launch its virtual-first behavioral health offering followed by a women's health specialty offering later this year.

Key Dates